APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antiangiogenic Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Antiangiogenic Drugs Market Analysis and Forecast 2026-2032

27 December 2025196 pages

Choose your research edition.

Industry ResearchAntiangiogenic Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Antiangiogenic Drugs Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Antiangiogenic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antiangiogenic Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Antiangiogenic Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Antiangiogenic Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Antiangiogenic Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Antiangiogenic Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Antiangiogenic Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Antiangiogenic Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Antiangiogenic Drugs include Chia Tai Tianqing, Sanofi, Jiangsu Hengrui Pharmaceuticals, Simcere, Roche, Pfizer, Novartis, Janssen Biotech and Exelixis, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Antiangiogenic Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Antiangiogenic Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Antiangiogenic Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antiangiogenic Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Antiangiogenic Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Antiangiogenic Drugs sales, projected growth trends, production technology, application and end-user industry.

Antiangiogenic Drugs Segment by Company

Chia Tai Tianqing

Sanofi

Jiangsu Hengrui Pharmaceuticals

Simcere

Roche

Pfizer

Novartis

Janssen Biotech

Exelixis

Eli Lilly

Eisai

Boehringer Ingelheim

Bayer

AstraZeneca

Antiangiogenic Drugs Segment by Type

Macromolecular Single-target Angiogenesis Inhibitor

Endogenous Pan-target Angiogenesis Inhibitor

Small Molecule Multi-target Angiogenesis Inhibitor

Antiangiogenic Drugs Segment by Application

Cancer Therapy

Inflammatory and Autoimmune Diseases

Ophthalmic Diseases

Other

Antiangiogenic Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiangiogenic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antiangiogenic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiangiogenic Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Antiangiogenic Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Antiangiogenic Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antiangiogenic Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Antiangiogenic Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Macromolecular Single-target Angiogenesis Inhibitor Major Manufacturers Table 3. Endogenous Pan-target Angiogenesis Inhibitor Major Manufacturers Table 4. Small Molecule Multi-target Angiogenesis Inhibitor Major Manufacturers Table 5. Global Antiangiogenic Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Cancer Therapy Major Manufacturers Table 7. Inflammatory and Autoimmune Diseases Major Manufacturers Table 8. Ophthalmic Diseases Major Manufacturers Table 9. Other Major Manufacturers Table 10. Antiangiogenic Drugs Industry Trends Table 11. Antiangiogenic Drugs Industry Drivers Table 12. Antiangiogenic Drugs Industry Opportunities and Challenges Table 13. Antiangiogenic Drugs Industry Restraints Table 14. Global Antiangiogenic Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Antiangiogenic Drugs Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Antiangiogenic Drugs Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Antiangiogenic Drugs Revenue Market Share by Region (2021-2026) Table 18. Global Antiangiogenic Drugs Revenue Market Share by Region (2027-2032) Table 19. Global Antiangiogenic Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 20. Global Antiangiogenic Drugs Sales by Region (2021-2026) & (K Units) Table 21. Global Antiangiogenic Drugs Sales by Region (2027-2032) & (K Units) Table 22. Global Antiangiogenic Drugs Sales Market Share by Region (2021-2026) Table 23. Global Antiangiogenic Drugs Sales Market Share by Region (2027-2032) Table 24. Global Antiangiogenic Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Antiangiogenic Drugs Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Antiangiogenic Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Antiangiogenic Drugs Sales Market Share by Manufacturers (2021-2026) Table 28. Global Antiangiogenic Drugs Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Antiangiogenic Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Antiangiogenic Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Antiangiogenic Drugs Manufacturers, Product Type & Application Table 32. Global Antiangiogenic Drugs Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Antiangiogenic Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Antiangiogenic Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Antiangiogenic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Antiangiogenic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Antiangiogenic Drugs Revenue Market Share by Type (2021-2026) Table 39. Global Antiangiogenic Drugs Revenue Market Share by Type (2027-2032) Table 40. Global Antiangiogenic Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 41. Global Antiangiogenic Drugs Sales by Type (2021-2026) & (K Units) Table 42. Global Antiangiogenic Drugs Sales by Type (2027-2032) & (K Units) Table 43. Global Antiangiogenic Drugs Sales Market Share by Type (2021-2026) Table 44. Global Antiangiogenic Drugs Sales Market Share by Type (2027-2032) Table 45. Global Antiangiogenic Drugs Price by Type (2021-2026) & (US$/Unit) Table 46. Global Antiangiogenic Drugs Price by Type (2027-2032) & (US$/Unit) Table 47. Global Antiangiogenic Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Antiangiogenic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Antiangiogenic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Antiangiogenic Drugs Revenue Market Share by Application (2021-2026) Table 51. Global Antiangiogenic Drugs Revenue Market Share by Application (2027-2032) Table 52. Global Antiangiogenic Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 53. Global Antiangiogenic Drugs Sales by Application (2021-2026) & (K Units) Table 54. Global Antiangiogenic Drugs Sales by Application (2027-2032) & (K Units) Table 55. Global Antiangiogenic Drugs Sales Market Share by Application (2021-2026) Table 56. Global Antiangiogenic Drugs Sales Market Share by Application (2027-2032) Table 57. Global Antiangiogenic Drugs Price by Application (2021-2026) & (US$/Unit) Table 58. Global Antiangiogenic Drugs Price by Application (2027-2032) & (US$/Unit) Table 59. Chia Tai Tianqing Company Information Table 60. Chia Tai Tianqing Business Overview Table 61. Chia Tai Tianqing Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Chia Tai Tianqing Antiangiogenic Drugs Product Portfolio Table 63. Chia Tai Tianqing Recent Development Table 64. Sanofi Company Information Table 65. Sanofi Business Overview Table 66. Sanofi Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Sanofi Antiangiogenic Drugs Product Portfolio Table 68. Sanofi Recent Development Table 69. Jiangsu Hengrui Pharmaceuticals Company Information Table 70. Jiangsu Hengrui Pharmaceuticals Business Overview Table 71. Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Product Portfolio Table 73. Jiangsu Hengrui Pharmaceuticals Recent Development Table 74. Simcere Company Information Table 75. Simcere Business Overview Table 76. Simcere Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Simcere Antiangiogenic Drugs Product Portfolio Table 78. Simcere Recent Development Table 79. Roche Company Information Table 80. Roche Business Overview Table 81. Roche Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Roche Antiangiogenic Drugs Product Portfolio Table 83. Roche Recent Development Table 84. Pfizer Company Information Table 85. Pfizer Business Overview Table 86. Pfizer Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Pfizer Antiangiogenic Drugs Product Portfolio Table 88. Pfizer Recent Development Table 89. Novartis Company Information Table 90. Novartis Business Overview Table 91. Novartis Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Novartis Antiangiogenic Drugs Product Portfolio Table 93. Novartis Recent Development Table 94. Janssen Biotech Company Information Table 95. Janssen Biotech Business Overview Table 96. Janssen Biotech Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Janssen Biotech Antiangiogenic Drugs Product Portfolio Table 98. Janssen Biotech Recent Development Table 99. Exelixis Company Information Table 100. Exelixis Business Overview Table 101. Exelixis Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Exelixis Antiangiogenic Drugs Product Portfolio Table 103. Exelixis Recent Development Table 104. Eli Lilly Company Information Table 105. Eli Lilly Business Overview Table 106. Eli Lilly Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Eli Lilly Antiangiogenic Drugs Product Portfolio Table 108. Eli Lilly Recent Development Table 109. Eisai Company Information Table 110. Eisai Business Overview Table 111. Eisai Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Eisai Antiangiogenic Drugs Product Portfolio Table 113. Eisai Recent Development Table 114. Boehringer Ingelheim Company Information Table 115. Boehringer Ingelheim Business Overview Table 116. Boehringer Ingelheim Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Boehringer Ingelheim Antiangiogenic Drugs Product Portfolio Table 118. Boehringer Ingelheim Recent Development Table 119. Bayer Company Information Table 120. Bayer Business Overview Table 121. Bayer Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Bayer Antiangiogenic Drugs Product Portfolio Table 123. Bayer Recent Development Table 124. AstraZeneca Company Information Table 125. AstraZeneca Business Overview Table 126. AstraZeneca Antiangiogenic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. AstraZeneca Antiangiogenic Drugs Product Portfolio Table 128. AstraZeneca Recent Development Table 129. North America Antiangiogenic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 130. North America Antiangiogenic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 131. North America Antiangiogenic Drugs Sales by Type (2021-2026) & (K Units) Table 132. North America Antiangiogenic Drugs Sales by Type (2027-2032) & (K Units) Table 133. North America Antiangiogenic Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 134. North America Antiangiogenic Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 135. North America Antiangiogenic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 136. North America Antiangiogenic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 137. North America Antiangiogenic Drugs Sales by Application (2021-2026) & (K Units) Table 138. North America Antiangiogenic Drugs Sales by Application (2027-2032) & (K Units) Table 139. North America Antiangiogenic Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 140. North America Antiangiogenic Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 141. North America Antiangiogenic Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. North America Antiangiogenic Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 143. North America Antiangiogenic Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 144. North America Antiangiogenic Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 145. North America Antiangiogenic Drugs Sales by Country (2021-2026) & (K Units) Table 146. North America Antiangiogenic Drugs Sales by Country (2027-2032) & (K Units) Table 147. North America Antiangiogenic Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 148. North America Antiangiogenic Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 149. United States Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 150. Canada Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 151. Mexico Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 152. Europe Antiangiogenic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 153. Europe Antiangiogenic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 154. Europe Antiangiogenic Drugs Sales by Type (2021-2026) & (K Units) Table 155. Europe Antiangiogenic Drugs Sales by Type (2027-2032) & (K Units) Table 156. Europe Antiangiogenic Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 157. Europe Antiangiogenic Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 158. Europe Antiangiogenic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 159. Europe Antiangiogenic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 160. Europe Antiangiogenic Drugs Sales by Application (2021-2026) & (K Units) Table 161. Europe Antiangiogenic Drugs Sales by Application (2027-2032) & (K Units) Table 162. Europe Antiangiogenic Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 163. Europe Antiangiogenic Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 164. Europe Antiangiogenic Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 165. Europe Antiangiogenic Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 166. Europe Antiangiogenic Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 167. Europe Antiangiogenic Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 168. Europe Antiangiogenic Drugs Sales by Country (2021-2026) & (K Units) Table 169. Europe Antiangiogenic Drugs Sales by Country (2027-2032) & (K Units) Table 170. Europe Antiangiogenic Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 171. Europe Antiangiogenic Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 172. Germany Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 173. France Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 174. U.K. Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 175. Italy Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 176. Russia Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 177. Spain Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 178. Netherlands Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 179. Switzerland Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 180. Sweden Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 181. Poland Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 182. China Antiangiogenic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 183. China Antiangiogenic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 184. China Antiangiogenic Drugs Sales by Type (2021-2026) & (K Units) Table 185. China Antiangiogenic Drugs Sales by Type (2027-2032) & (K Units) Table 186. China Antiangiogenic Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 187. China Antiangiogenic Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 188. China Antiangiogenic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 189. China Antiangiogenic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 190. China Antiangiogenic Drugs Sales by Application (2021-2026) & (K Units) Table 191. China Antiangiogenic Drugs Sales by Application (2027-2032) & (K Units) Table 192. China Antiangiogenic Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 193. China Antiangiogenic Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 194. Asia Antiangiogenic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 195. Asia Antiangiogenic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 196. Asia Antiangiogenic Drugs Sales by Type (2021-2026) & (K Units) Table 197. Asia Antiangiogenic Drugs Sales by Type (2027-2032) & (K Units) Table 198. Asia Antiangiogenic Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 199. Asia Antiangiogenic Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 200. Asia Antiangiogenic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 201. Asia Antiangiogenic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 202. Asia Antiangiogenic Drugs Sales by Application (2021-2026) & (K Units) Table 203. Asia Antiangiogenic Drugs Sales by Application (2027-2032) & (K Units) Table 204. Asia Antiangiogenic Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 205. Asia Antiangiogenic Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 206. Asia Antiangiogenic Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 207. Asia Antiangiogenic Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 208. Asia Antiangiogenic Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 209. Asia Antiangiogenic Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 210. Asia Antiangiogenic Drugs Sales by Country (2021-2026) & (K Units) Table 211. Asia Antiangiogenic Drugs Sales by Country (2027-2032) & (K Units) Table 212. Asia Antiangiogenic Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 213. Asia Antiangiogenic Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 214. Japan Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 215. South Korea Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 216. India Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 217. Australia Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 218. Taiwan Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 219. Southeast Asia Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 220. SAMEA Antiangiogenic Drugs Revenue by Type (2021-2026) & (US$ Million) Table 221. SAMEA Antiangiogenic Drugs Revenue by Type (2027-2032) & (US$ Million) Table 222. SAMEA Antiangiogenic Drugs Sales by Type (2021-2026) & (K Units) Table 223. SAMEA Antiangiogenic Drugs Sales by Type (2027-2032) & (K Units) Table 224. SAMEA Antiangiogenic Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 225. SAMEA Antiangiogenic Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 226. SAMEA Antiangiogenic Drugs Revenue by Application (2021-2026) & (US$ Million) Table 227. SAMEA Antiangiogenic Drugs Revenue by Application (2027-2032) & (US$ Million) Table 228. SAMEA Antiangiogenic Drugs Sales by Application (2021-2026) & (K Units) Table 229. SAMEA Antiangiogenic Drugs Sales by Application (2027-2032) & (K Units) Table 230. SAMEA Antiangiogenic Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 231. SAMEA Antiangiogenic Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 232. SAMEA Antiangiogenic Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 233. SAMEA Antiangiogenic Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 234. SAMEA Antiangiogenic Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 235. SAMEA Antiangiogenic Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 236. SAMEA Antiangiogenic Drugs Sales by Country (2021-2026) & (K Units) Table 237. SAMEA Antiangiogenic Drugs Sales by Country (2027-2032) & (K Units) Table 238. SAMEA Antiangiogenic Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 239. SAMEA Antiangiogenic Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 240. Brazil Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 241. Argentina Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 242. Chile Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 243. Colombia Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 244. Peru Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 245. Saudi Arabia Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 246. Israel Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 247. UAE Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 248. Turkey Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 249. Iran Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 250. Egypt Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Table 251. Key Raw Materials Table 252. Raw Materials Key Suppliers Table 253. Antiangiogenic Drugs Distributors List Table 254. Antiangiogenic Drugs Customers List Table 255. Research Programs/Design for This Report Table 256. Authors List of This Report Table 257. Secondary Sources Table 258. Primary Sources List of Figures Figure 1. Antiangiogenic Drugs Image Figure 2. Global Antiangiogenic Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antiangiogenic Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Macromolecular Single-target Angiogenesis Inhibitor Image Figure 5. Endogenous Pan-target Angiogenesis Inhibitor Image Figure 6. Small Molecule Multi-target Angiogenesis Inhibitor Image Figure 7. Global Antiangiogenic Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Antiangiogenic Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Cancer Therapy Image Figure 10. Inflammatory and Autoimmune Diseases Image Figure 11. Ophthalmic Diseases Image Figure 12. Other Image Figure 13. Global Antiangiogenic Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Antiangiogenic Drugs Revenue (2021-2032) & (US$ Million) Figure 15. Global Antiangiogenic Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Antiangiogenic Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Antiangiogenic Drugs Revenue Market Share by Region (2021-2032) Figure 18. Global Antiangiogenic Drugs Sales (2021-2032) & (K Units) Figure 19. Global Antiangiogenic Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 20. Global Antiangiogenic Drugs Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Antiangiogenic Drugs Sales YoY (2021-2032) & (K Units) Figure 22. Europe Antiangiogenic Drugs Sales YoY (2021-2032) & (K Units) Figure 23. China Antiangiogenic Drugs Sales YoY (2021-2032) & (K Units) Figure 24. Asia (Excluding China) Antiangiogenic Drugs Sales YoY (2021-2032) & (K Units) Figure 25. South America, Middle East and Africa Antiangiogenic Drugs Sales YoY (2021-2032) & (K Units) Figure 26. Global Antiangiogenic Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Antiangiogenic Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Antiangiogenic Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Antiangiogenic Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Antiangiogenic Drugs Revenue Market Share by Type (2021-2032) Figure 32. Global Antiangiogenic Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 33. Global Antiangiogenic Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Antiangiogenic Drugs Sales Market Share by Type (2021-2032) Figure 35. Global Antiangiogenic Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Antiangiogenic Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Antiangiogenic Drugs Revenue Market Share by Application (2021-2032) Figure 38. Global Antiangiogenic Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 39. Global Antiangiogenic Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Antiangiogenic Drugs Sales Market Share by Application (2021-2032) Figure 41. North America Antiangiogenic Drugs Revenue Share by Type (2021-2032) Figure 42. North America Antiangiogenic Drugs Sales Share by Type (2021-2032) Figure 43. North America Antiangiogenic Drugs Revenue Share by Application (2021-2032) Figure 44. North America Antiangiogenic Drugs Sales Share by Application (2021-2032) Figure 45. North America Antiangiogenic Drugs Revenue Share by Country (2021-2032) Figure 46. North America Antiangiogenic Drugs Sales Share by Country (2021-2032) Figure 47. Europe Antiangiogenic Drugs Revenue Share by Type (2021-2032) Figure 48. Europe Antiangiogenic Drugs Sales Share by Type (2021-2032) Figure 49. Europe Antiangiogenic Drugs Revenue Share by Application (2021-2032) Figure 50. Europe Antiangiogenic Drugs Sales Share by Application (2021-2032) Figure 51. Europe Antiangiogenic Drugs Revenue Share by Country (2021-2032) Figure 52. Europe Antiangiogenic Drugs Sales Share by Country (2021-2032) Figure 53. China Antiangiogenic Drugs Revenue Share by Type (2021-2032) Figure 54. China Antiangiogenic Drugs Sales Share by Type (2021-2032) Figure 55. China Antiangiogenic Drugs Revenue Share by Application (2021-2032) Figure 56. China Antiangiogenic Drugs Sales Share by Application (2021-2032) Figure 57. Asia Antiangiogenic Drugs Revenue Share by Type (2021-2032) Figure 58. Asia Antiangiogenic Drugs Sales Share by Type (2021-2032) Figure 59. Asia Antiangiogenic Drugs Revenue Share by Application (2021-2032) Figure 60. Asia Antiangiogenic Drugs Sales Share by Application (2021-2032) Figure 61. Asia Antiangiogenic Drugs Revenue Share by Country (2021-2032) Figure 62. Asia Antiangiogenic Drugs Sales Share by Country (2021-2032) Figure 63. SAMEA Antiangiogenic Drugs Revenue Share by Type (2021-2032) Figure 64. SAMEA Antiangiogenic Drugs Sales Share by Type (2021-2032) Figure 65. SAMEA Antiangiogenic Drugs Revenue Share by Application (2021-2032) Figure 66. SAMEA Antiangiogenic Drugs Sales Share by Application (2021-2032) Figure 67. SAMEA Antiangiogenic Drugs Revenue Share by Country (2021-2032) Figure 68. SAMEA Antiangiogenic Drugs Sales Share by Country (2021-2032) Figure 69. Antiangiogenic Drugs Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Antiangiogenic Drugs Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Macromolecular Single-target Angiogenesis Inhibitor
  • Endogenous Pan-target Angiogenesis Inhibitor
  • Small Molecule Multi-target Angiogenesis Inhibitor
Applications
  • Cancer Therapy
  • Inflammatory and Autoimmune Diseases
  • Ophthalmic Diseases
  • Other
Companies covered
  • Chia Tai Tianqing
  • Sanofi
  • Jiangsu Hengrui Pharmaceuticals
  • Simcere
  • Roche
  • Pfizer
  • Novartis
  • Janssen Biotech
  • Exelixis
  • Eli Lilly
  • Eisai
  • Boehringer Ingelheim
  • Bayer
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Antiangiogenic Drugs Market by Type
  3. 1.2.1 Global Antiangiogenic Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Macromolecular Single-target Angiogenesis Inhibitor
  5. 1.2.3 Endogenous Pan-target Angiogenesis Inhibitor
  6. 1.2.4 Small Molecule Multi-target Angiogenesis Inhibitor
  7. 1.3 Antiangiogenic Drugs Market by Application
  8. 1.3.1 Global Antiangiogenic Drugs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Cancer Therapy
  10. 1.3.3 Inflammatory and Autoimmune Diseases
  11. 1.3.4 Ophthalmic Diseases
  12. 1.3.5 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Antiangiogenic Drugs Market Dynamics
  1. 2.1 Antiangiogenic Drugs Industry Trends
  2. 2.2 Antiangiogenic Drugs Industry Drivers
  3. 2.3 Antiangiogenic Drugs Industry Opportunities and Challenges
  4. 2.4 Antiangiogenic Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Antiangiogenic Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Antiangiogenic Drugs Revenue by Region
  3. 3.2.1 Global Antiangiogenic Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Antiangiogenic Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Antiangiogenic Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Antiangiogenic Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Antiangiogenic Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Antiangiogenic Drugs Sales by Region
  9. 3.4.1 Global Antiangiogenic Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Antiangiogenic Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Antiangiogenic Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Antiangiogenic Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Antiangiogenic Drugs Revenue by Manufacturers
  2. 4.1.1 Global Antiangiogenic Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Antiangiogenic Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Antiangiogenic Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Antiangiogenic Drugs Sales by Manufacturers
  6. 4.2.1 Global Antiangiogenic Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Antiangiogenic Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Antiangiogenic Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Antiangiogenic Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Antiangiogenic Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Antiangiogenic Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Antiangiogenic Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Antiangiogenic Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Antiangiogenic Drugs Market CR5 and HHI
  16. 4.8.2 2025 Antiangiogenic Drugs Tier 1, Tier 2, and Tier 3
5 Antiangiogenic Drugs Market by Type
  1. 5.1 Global Antiangiogenic Drugs Revenue by Type
  2. 5.1.1 Global Antiangiogenic Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Antiangiogenic Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Antiangiogenic Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Antiangiogenic Drugs Sales by Type
  6. 5.2.1 Global Antiangiogenic Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antiangiogenic Drugs Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Antiangiogenic Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Antiangiogenic Drugs Price by Type
6 Antiangiogenic Drugs Market by Application
  1. 6.1 Global Antiangiogenic Drugs Revenue by Application
  2. 6.1.1 Global Antiangiogenic Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Antiangiogenic Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Antiangiogenic Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Antiangiogenic Drugs Sales by Application
  6. 6.2.1 Global Antiangiogenic Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Antiangiogenic Drugs Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Antiangiogenic Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Antiangiogenic Drugs Price by Application
7 Company Profiles
  1. 7.1 Chia Tai Tianqing
  2. 7.1.1 Chia Tai Tianqing Company Information
  3. 7.1.2 Chia Tai Tianqing Business Overview
  4. 7.1.3 Chia Tai Tianqing Antiangiogenic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Chia Tai Tianqing Antiangiogenic Drugs Product Portfolio
  6. 7.1.5 Chia Tai Tianqing Recent Developments
  7. 7.2 Sanofi
  8. 7.2.1 Sanofi Company Information
  9. 7.2.2 Sanofi Business Overview
  10. 7.2.3 Sanofi Antiangiogenic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Antiangiogenic Drugs Product Portfolio
  12. 7.2.5 Sanofi Recent Developments
  13. 7.3 Jiangsu Hengrui Pharmaceuticals
  14. 7.3.1 Jiangsu Hengrui Pharmaceuticals Company Information
  15. 7.3.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  16. 7.3.3 Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Product Portfolio
  18. 7.3.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  19. 7.4 Simcere
  20. 7.4.1 Simcere Company Information
  21. 7.4.2 Simcere Business Overview
  22. 7.4.3 Simcere Antiangiogenic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Simcere Antiangiogenic Drugs Product Portfolio
  24. 7.4.5 Simcere Recent Developments
  25. 7.5 Roche
  26. 7.5.1 Roche Company Information
  27. 7.5.2 Roche Business Overview
  28. 7.5.3 Roche Antiangiogenic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Roche Antiangiogenic Drugs Product Portfolio
  30. 7.5.5 Roche Recent Developments
  31. 7.6 Pfizer
  32. 7.6.1 Pfizer Company Information
  33. 7.6.2 Pfizer Business Overview
  34. 7.6.3 Pfizer Antiangiogenic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer Antiangiogenic Drugs Product Portfolio
  36. 7.6.5 Pfizer Recent Developments
  37. 7.7 Novartis
  38. 7.7.1 Novartis Company Information
  39. 7.7.2 Novartis Business Overview
  40. 7.7.3 Novartis Antiangiogenic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Novartis Antiangiogenic Drugs Product Portfolio
  42. 7.7.5 Novartis Recent Developments
  43. 7.8 Janssen Biotech
  44. 7.8.1 Janssen Biotech Company Information
  45. 7.8.2 Janssen Biotech Business Overview
  46. 7.8.3 Janssen Biotech Antiangiogenic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Janssen Biotech Antiangiogenic Drugs Product Portfolio
  48. 7.8.5 Janssen Biotech Recent Developments
  49. 7.9 Exelixis
  50. 7.9.1 Exelixis Company Information
  51. 7.9.2 Exelixis Business Overview
  52. 7.9.3 Exelixis Antiangiogenic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Exelixis Antiangiogenic Drugs Product Portfolio
  54. 7.9.5 Exelixis Recent Developments
  55. 7.10 Eli Lilly
  56. 7.10.1 Eli Lilly Company Information
  57. 7.10.2 Eli Lilly Business Overview
  58. 7.10.3 Eli Lilly Antiangiogenic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Eli Lilly Antiangiogenic Drugs Product Portfolio
  60. 7.10.5 Eli Lilly Recent Developments
  61. 7.11 Eisai
  62. 7.11.1 Eisai Company Information
  63. 7.11.2 Eisai Business Overview
  64. 7.11.3 Eisai Antiangiogenic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Eisai Antiangiogenic Drugs Product Portfolio
  66. 7.11.5 Eisai Recent Developments
  67. 7.12 Boehringer Ingelheim
  68. 7.12.1 Boehringer Ingelheim Company Information
  69. 7.12.2 Boehringer Ingelheim Business Overview
  70. 7.12.3 Boehringer Ingelheim Antiangiogenic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Boehringer Ingelheim Antiangiogenic Drugs Product Portfolio
  72. 7.12.5 Boehringer Ingelheim Recent Developments
  73. 7.13 Bayer
  74. 7.13.1 Bayer Company Information
  75. 7.13.2 Bayer Business Overview
  76. 7.13.3 Bayer Antiangiogenic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Bayer Antiangiogenic Drugs Product Portfolio
  78. 7.13.5 Bayer Recent Developments
  79. 7.14 AstraZeneca
  80. 7.14.1 AstraZeneca Company Information
  81. 7.14.2 AstraZeneca Business Overview
  82. 7.14.3 AstraZeneca Antiangiogenic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 AstraZeneca Antiangiogenic Drugs Product Portfolio
  84. 7.14.5 AstraZeneca Recent Developments
8 North America
  1. 8.1 North America Antiangiogenic Drugs Market Size by Type
  2. 8.1.1 North America Antiangiogenic Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Antiangiogenic Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Antiangiogenic Drugs Price by Type (2021-2032)
  5. 8.2 North America Antiangiogenic Drugs Market Size by Application
  6. 8.2.1 North America Antiangiogenic Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Antiangiogenic Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Antiangiogenic Drugs Price by Application (2021-2032)
  9. 8.3 North America Antiangiogenic Drugs Market Size by Country
  10. 8.3.1 North America Antiangiogenic Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Antiangiogenic Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Antiangiogenic Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Antiangiogenic Drugs Market Size by Type
  2. 9.1.1 Europe Antiangiogenic Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Antiangiogenic Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Antiangiogenic Drugs Price by Type (2021-2032)
  5. 9.2 Europe Antiangiogenic Drugs Market Size by Application
  6. 9.2.1 Europe Antiangiogenic Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Antiangiogenic Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Antiangiogenic Drugs Price by Application (2021-2032)
  9. 9.3 Europe Antiangiogenic Drugs Market Size by Country
  10. 9.3.1 Europe Antiangiogenic Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Antiangiogenic Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Antiangiogenic Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Antiangiogenic Drugs Market Size by Type
  2. 10.1.1 China Antiangiogenic Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Antiangiogenic Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Antiangiogenic Drugs Price by Type (2021-2032)
  5. 10.2 China Antiangiogenic Drugs Market Size by Application
  6. 10.2.1 China Antiangiogenic Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Antiangiogenic Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Antiangiogenic Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Antiangiogenic Drugs Market Size by Type
  2. 11.1.1 Asia Antiangiogenic Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Antiangiogenic Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Antiangiogenic Drugs Price by Type (2021-2032)
  5. 11.2 Asia Antiangiogenic Drugs Market Size by Application
  6. 11.2.1 Asia Antiangiogenic Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Antiangiogenic Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Antiangiogenic Drugs Price by Application (2021-2032)
  9. 11.3 Asia Antiangiogenic Drugs Market Size by Country
  10. 11.3.1 Asia Antiangiogenic Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Antiangiogenic Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Antiangiogenic Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Antiangiogenic Drugs Market Size by Type
  2. 12.1.1 SAMEA Antiangiogenic Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Antiangiogenic Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Antiangiogenic Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Antiangiogenic Drugs Market Size by Application
  6. 12.2.1 SAMEA Antiangiogenic Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Antiangiogenic Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Antiangiogenic Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Antiangiogenic Drugs Market Size by Country
  10. 12.3.1 SAMEA Antiangiogenic Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Antiangiogenic Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Antiangiogenic Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Antiangiogenic Drugs Value Chain Analysis
  2. 13.1.1 Antiangiogenic Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Antiangiogenic Drugs Production Mode & Process
  6. 13.2 Antiangiogenic Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Antiangiogenic Drugs Distributors
  9. 13.2.3 Antiangiogenic Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst